Cooperation between Epstein-Barr Virus Immune Evasion Proteins Spreads Protection from CD8 T Cell Recognition across All Three Phases of the Lytic Cycle

English version České info

Epstein Barr Virus (EBV), an oncogenic herpesvirus, infects and persists asymptomatically in the majority of humans. In immunocompetent individuals, EBV co-exists with its host as a lifelong infection in the face of strong anti-viral CD8+ T-cell responses. Evasion of this immune-response is presumed to be due in part to immune-modulating mechanisms of certain EBV-encoded proteins expressed during lytic cycle replication. Three such proteins (BNLF2a, BGLF5 and BILF1) have been identified biochemically as able to interfere with HLA-class I antigen presentation. In this study we investigated these proteins in the context of EBV-infected cells in lytic cycle, and their functional recognition by EBV virus-specific CD8+ T-cells. A novel feature of EBV biology was revealed; rather than demonstrating simple redundancy, evasion proteins effect optimum temporal protection at different phases of lytic cycle. BNLF2a strongly inhibited CD8+ T-cell recognition immediately after the EBV-infected cells entered lytic cycle, with its influence waning upon progression to later phases of lytic cycle. Conversely, BILF1 strongly inhibited recognition predominantly at the late phase of lytic cycle. Unexpectedly, despite its well-characterised molecular functions, BGLF5 had relatively little effect on recognition at any stage of lytic cycle. Our results help to explain the previously-identified unusual pattern of immunodominance of anti-EBV CD8+ T-cell responses.

Vyšlo v časopise: Cooperation between Epstein-Barr Virus Immune Evasion Proteins Spreads Protection from CD8 T Cell Recognition across All Three Phases of the Lytic Cycle. PLoS Pathog 10(8): e32767. doi:10.1371/journal.ppat.1004322
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004322

Souhrn

Zdroje

1. ZuckermanRA, LimayeAP (2013) Varicella zoster virus (VZV) and herpes simplex virus (HSV) in solid organ transplant patients. Am J Transplant 13 Suppl 3: 55–66; quiz 66.

2. HebartH, EinseleH (2004) Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 65: 432–436.

3. ZerrDM, CoreyL, KimHW, HuangML, NguyL, et al. (2005) Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 40: 932–940.

4. GottschalkS, RooneyCM, HeslopHE (2005) Post-transplant lymphoproliferative disorders. Annu Rev Med 56: 29–44.

5. GerdemannU, KeukensL, KeirnanJM, KatariUL, NguyenCT, et al. (2013) Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood 121: 207–218.

6. LeenAM, MyersGD, SiliU, HulsMH, WeissH, et al. (2006) Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12: 1160–1166.

7. HislopAD, TaylorGS, SauceD, RickinsonAB (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587–617.

8. StarzlTE, NalesnikMA, PorterKA, HoM, IwatsukiS, et al. (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (i) 583–587.

9. Rickinson AB, Kieff E (2007) Epstein-Barr virus. In: Knipe DM, Howley PM, editors. Fields Virology, 5th Edition. Philadelphia: Lippincott, Williams & Wilkins. pp. 2655–2700.

10. RoweM, KellyGL, BellAI, RickinsonAB (2009) Burkitt's lymphoma: The Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol 19: 377–388.

11. HadinotoV, ShapiroM, SunCC, Thorley-LawsonDA (2009) The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 5: 3.

12. RessingME, KeatingSE, van LeeuwenD, Koppers-LalicD, PappworthIY, et al. (2005) Impaired Transporter Associated with Antigen Processing-dependent peptide transport during productive EBV Infection. J Immunol 174: 6829–6838.

13. KeatingS, PrinceS, JonesM, RoweM (2002) The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J Virol 76: 8179–8188.

14. PudneyVA, LeeseAM, RickinsonAB, HislopAD (2005) CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med 201: 349–360.

15. HislopAD, RessingME, van LeeuwenD, PudneyVA, HorstD, et al. (2007) A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204: 1863–1873.

16. ZuoJ, CurrinA, GriffinBD, Shannon-LoweC, ThomasWA, et al. (2009) The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog 5: 2.

17. RoweM, GlaunsingerB, van LeeuwenD, ZuoJ, SweetmanD, et al. (2007) Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci U S A 104: 3366–3371.

18. RoweM, ZuoJ (2010) Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. Microbes Infect 12: 173–181.

19. CroftNP, Shannon-LoweC, BellAI, HorstD, KremmerE, et al. (2009) Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog 5: e1000490.

20. HorstD, FavaloroV, VilardiF, van LeeuwenHC, GarstkaMA, et al. (2011) EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP. J Immunol 186: 3594–3605.

21. HorstD, van LeeuwenD, CroftNP, GarstkaMA, HislopAD, et al. (2009) Specific Targeting of the EBV Lytic Phase Protein BNLF2a to the Transporter Associated with Antigen Processing Results in Impairment of HLA Class I-Restricted Antigen Presentation. J Immunol 182: 2313–2324.

22. BuissonM, GeouiT, FlotD, TarbouriechN, RessingME, et al. (2009) A bridge crosses the active-site canyon of the Epstein-Barr virus nuclease with DNase and RNase activities. J Mol Biol 391: 717–728.

23. ZuoJ, ThomasW, van LeeuwenD, MiddeldorpJM, WiertzEJ, et al. (2008) The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. J Virol 82: 2385–2393.

24. ZuoJ, QuinnLL, TamblynJ, ThomasWA, FeederleR, et al. (2011) The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways. J Virol 85: 1604–1614.

25. GriffinBD, GramAM, MulderA, Van LeeuwenD, ClaasFH, et al. (2013) EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail. J Immunol 190: 1672–1684.

26. FeederleR, BannertH, LipsH, Muller-LantzschN, DelecluseHJ (2009) The Epstein-Barr virus alkaline exonuclease BGLF5 serves pleiotropic functions in virus replication. J Virol 83: 4952–4962.

27. TiggesMA, LengS, JohnsonDC, BurkeRL (1996) Human herpes simplex virus (HSV)-specific CD8+ CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. J Immunol 156: 3901–3910.

28. GaribalJ, HollvilleE, BellAI, KellyGL, RenoufB, et al. (2007) Truncated form of the Epstein-Barr virus protein EBNA-LP protcts against caspase-dependent apoptosis by inhibiting protein phosphatase 2A. Journal of Virology 81: 7598–7607.

29. HislopAD, RessingME, van LeeuwenD, PudneyVA, HorstD, et al. (2007) A CD8(+) T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. Journal of Experimental Medicine 204: 1863–1873.

30. KellyGL, StylianouJ, BellAI, WeiW, RoweM, et al. (2007) Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-Myc expressing Burkitt Lymphoma cells. Blood 110: 470a–470a.

31. AhnK, GruhlerA, GalochaB, JonesTR, WiertzEJ, et al. (1997) The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 6: 613–621.

32. HengelH, KoopmannJO, FlohrT, MuranyiW, GoulmyE, et al. (1997) A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 6: 623–632.

33. HislopAD, TaylorGS, SauceD, RickinsonAB (2007) Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. Annual Review of Immunology 25: 587–617.

34. ChijiokeO, AzziT, NadalD, MunzC (2013) Innate immune responses against Epstein Barr virus infection. J Leukoc Biol 94: 1185–1190.

35. PappworthIY, WangEC, RoweM (2007) The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol 81: 474–482.

36. BeisserPS, VerzijlD, GruijthuijsenYK, BeukenE, SmitMJ, et al. (2005) The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase. J Virol 79: 441–449.

37. PaulsenSJ, RosenkildeMM, Eugen-OlsenJ, KledalTN (2005) Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J Virol 79: 536–546.

38. CoffeyAJ, BrooksbankRA, BrandauO, OohashiT, HowellGR, et al. (1998) Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 20: 129–135.

39. HislopAD, PalendiraU, LeeseAM, ArkwrightPD, RohrlichPS, et al. (2010) Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood 116: 3249–3257.

40. NicholsKE, HarkinDP, LevitzS, KrainerM, KolquistKA, et al. (1998) Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A 95: 13765–13770.

41. BuscheA, JirmoAC, WeltenSP, ZischkeJ, NoackJ, et al. (2013) Priming of CD8+ T cells against cytomegalovirus-encoded antigens is dominated by cross-presentation. J Immunol 190: 2767–2777.

42. MunksMW, PintoAK, DoomCM, HillAB (2007) Viral interference with antigen presentation does not alter acute or chronic CD8 T cell immunodominance in murine cytomegalovirus infection. J Immunol 178: 7235–7241.

43. SnyderCM, AllanJE, BonnettEL, DoomCM, HillAB (2010) Cross-presentation of a spread-defective MCMV is sufficient to prime the majority of virus-specific CD8+ T cells. PLoS One 5: 0009681.

44. FeederleR, KostM, BaumannM, JanzA, DrouetE, et al. (2000) The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 19: 3080–3089.

45. ZuoJ, QuinnLL, TamblynJ, ThomasWA, FeederleR, et al. (2011) The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting MHC class I molecules trafficking on both the exocytic and endocytic pathways. J Virol 85: 1604–1614.

46. AbbottRJ, QuinnLL, LeeseAM, ScholesHM, PachnioA, et al. (2013) CD8+ T Cell Responses to Lytic EBV Infection: Late Antigen Specificities as Subdominant Components of the Total Response. J Immunol 191: 5398–5409.

47. LongHM, HaighTA, GudgeonNH, LeenAM, TsangCW, et al. (2005) CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol 79: 4896–4907.

48. BlumJS, WearschPA, CresswellP (2013) Pathways of antigen processing. Annu Rev Immunol 31: 443–473.

49. CroftNP, SmithSA, WongYC, TanCT, DudekNL, et al. (2013) Kinetics of Antigen Expression and Epitope Presentation during Virus Infection. PLoS Pathogens 9: e1003129.

50. MackayLK, LongHM, BrooksJM, TaylorGS, LeungCS, et al. (2009) T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display. PLoS Pathog 5: e1000699.

51. RoweM, JonesM (2001) Epstein-Barr virus protocols. Detection of EBV latent proteins by Western Blotting. Methods in Molecular Biology 174: 229–242.

52. FachirohJ, SchoutenT, HariwiyantoB, ParamitaDK, HarijadiA, et al. (2004) Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis 190: 53–62.

53. YoungLS, LauR, RoweM, NiedobitekG, PackhamG, et al. (1991) Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral “hairy” leukoplakia. J Virol 65: 2868–2874.

54. RoweM, LearAL, Croom-CarterD, DaviesAH, RickinsonAB (1992) Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 66: 122–131.